2025 CCHIO | Professor Song Chuan Gui: ADC Drugs
Compiled by: Oncology NewsSource: Oncology News In the treatment of hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer, CDK4/6 inhibitors combined with endocrine therapy have become the first-line standard regimen. However, treatment options after resistance to CDK4/6 inhibitors or endocrine therapy remain a significant clinical challenge. With the rise of antibody-drug conjugates (ADCs), the treatment … Read more